Physician profile
Haowei Han
NPI 1043878978
$9,871.26
in general payments reported to CMS, 2019-2025
24 companies · $2,152 in 2025
The $2,152 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40.35 · 2022: $500 · 2023: $5,583 · 2024: $1,597 · 2025: $2,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,814 · Food and Beverage: $4,518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,813.72 |
| Food and Beverage | $4,517.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $4,785.12 | 2021-2025 | |
| Genzyme Corporation | $594.42 | 2021-2025 | |
| Pfizer INC. | $577.73 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $548.71 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $478.50 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $416.49 | 2023-2025 | Sotyktu |
| Ucb, INC. | $364.13 | 2024-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $285.30 | 2023-2025 | Cabtreo, Siliq |
| Abbvie INC. | $267.67 | 2022-2025 | |
| Incyte Corporation | $209.58 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $201.88 | 2024-2025 | |
| Dermavant Sciences, INC. | $187.07 | 2023-2024 | Vtama |
| Biofrontera INC. | $159.22 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.30 | 2024-2025 | Spevigo, Cyltezo |
| Merck Sharp & Dohme LLC | $113.26 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $93.79 | 2023-2024 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $84.83 | 2025 | Nemluvio |
| Almirall LLC | $80.00 | 2025 | Klisyri |
| Takeda Pharmaceuticals U.S.A., INC. | $65.99 | 2025 | |
| Organon LLC | $59.76 | 2025 | Vtama |
| Leo Pharma INC. | $52.45 | 2025 | Anzupgo |
| Verrica Pharmaceuticals INC. | $50.17 | 2024-2025 | Ycanth |
| Epi Health, LLC | $42.21 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haowei Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.